Pacira Biosciences, Inc. (PCRX)
24.76
-0.29
(-1.16%)
USD |
NASDAQ |
Oct 06, 16:00
24.76
0.00 (0.00%)
After-Hours: 20:00
Pacira Biosciences Enterprise Value : 1.147B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 1.147B |
| October 05, 2026 | 1.159B |
| October 02, 2026 | 1.165B |
| October 01, 2026 | 1.157B |
| September 30, 2026 | 1.159B |
| September 29, 2026 | 1.183B |
| September 28, 2026 | 1.172B |
| September 25, 2026 | 1.161B |
| September 24, 2026 | 1.179B |
| September 23, 2026 | 1.142B |
| September 22, 2026 | 1.145B |
| September 21, 2026 | 1.121B |
| September 18, 2026 | 1.144B |
| September 17, 2026 | 1.136B |
| September 16, 2026 | 1.153B |
| September 15, 2026 | 1.120B |
| September 14, 2026 | 1.144B |
| September 11, 2026 | 1.171B |
| September 10, 2026 | 1.163B |
| September 09, 2026 | 1.192B |
| September 08, 2026 | 1.191B |
| September 04, 2026 | 1.210B |
| September 03, 2026 | 1.220B |
| September 02, 2026 | 1.220B |
| September 01, 2026 | 1.215B |
| Date | Value |
|---|---|
| August 31, 2026 | 1.192B |
| August 28, 2026 | 1.187B |
| August 27, 2026 | 1.190B |
| August 26, 2026 | 1.192B |
| August 25, 2026 | 1.178B |
| August 24, 2026 | 1.151B |
| August 21, 2026 | 1.144B |
| August 20, 2026 | 1.110B |
| August 19, 2026 | 1.131B |
| August 18, 2026 | 1.117B |
| August 17, 2026 | 1.087B |
| August 14, 2026 | 1.077B |
| August 13, 2026 | 1.084B |
| August 12, 2026 | 1.105B |
| August 11, 2026 | 1.132B |
| August 10, 2026 | 1.134B |
| August 07, 2026 | 1.157B |
| August 06, 2026 | 1.180B |
| August 05, 2026 | 1.151B |
| August 04, 2026 | 1.261B |
| August 03, 2026 | 1.233B |
| July 31, 2026 | 1.213B |
| July 30, 2026 | 1.235B |
| July 29, 2026 | 1.212B |
| July 28, 2026 | 1.229B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 641.85B |
| Liquidia Corp. | 2.207B |
| ANI Pharmaceuticals, Inc. | 1.878B |
| Corcept Therapeutics, Inc. | 12.61B |
| Veru, Inc. | 19.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.653M |
| Revenue (Quarterly) | 192.40M |
| Total Expenses (Quarterly) | 187.75M |
| EPS Diluted (Quarterly) | 0.1155 |
| Gross Profit Margin (Quarterly) | 69.60% |
| Profit Margin (Quarterly) | 2.42% |
| Earnings Yield | 1.40% |
| Operating Earnings Yield | 2.65% |
| Normalized Earnings Yield | 1.968 |